First patients to test new cancer drug DXC014 in groundbreaking trial
NCT ID NCT07177937
Summary
This is the first-ever study in humans of a new drug called DXC014, designed for people with advanced solid tumors like lung cancer, melanoma, and prostate cancer. The main goal is to find a safe dose and understand how the body processes the drug. Researchers will also look for early signs that the drug might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hunan Cancer Hospital
Changsha, Hunan, 410000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.